On Wednesday AC Immune (NASDAQ: ACIU) rose 0.84% to $7.19 with an insignificant trading volume of 30,887 shares when the average volume is 82,295. Today ACIU instantly jumped 62.17% premarket. What is driving it to rise so fast?
AC Immune starts phase 1b/2a clinical trial for the treatment of Alzheimer’s disease which is seemingly not real to be healed but can be prevented at early stages. The current phase uses anti-Tau vaccines ACI-35.030, which is developed in collaboration with Janssen Pharmaceuticals.
Not many biotech companies fighting against Alzheimer’s disease now as COVID-19 pandemic has created a brutal race in developing an effective vaccine as soon as possible. However, some investors prefer investing in other biotech companies that fight other serious diseases.
Editor in Chief.
Living in the era of dynamic tech change Alex decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring in Finance) writing for technology and as well as finance has been one of the precious aspects of his life